This compound is primarily utilized in the development of targeted drug delivery systems, particularly in the field of cancer therapy. Its structure allows it to function as a prodrug, where it remains inactive until it reaches the specific target site, such as tumor cells. Once there, it is cleaved by enzymes like cathepsins, which are often overexpressed in cancer cells, releasing the active drug, rifabutin. This targeted approach helps minimize damage to healthy tissues and reduces systemic side effects. Additionally, it is explored in antibody-drug conjugates (ADCs), where it is linked to antibodies that specifically bind to cancer cell markers, enhancing the precision of drug delivery. This makes it a promising candidate for improving the efficacy and safety of chemotherapeutic treatments.